MedPharm Names Bill Humphries as New CEO Amid Strategic Expansion
Company - People | Feb 04, 2025 | Ampersand Capital Partners
MedPharm, a distinguished entity in the field of topical and transdermal contract drug development and manufacturing, has appointed Bill Humphries as its new CEO to lead the company into its next phase of strategic growth. This move follows the recent merger of MedPharm with Tergus Pharma, enhancing its scientific, clinical trial manufacturing, and commercial production capabilities. Bill Humphries brings considerable expertise with over 36 years in pharmaceutical and life sciences leadership, having previously led companies like Alcami and Isosceles Pharmaceuticals. Under his direction, MedPharm aims to leverage its capabilities to serve an expansive client base and set new standards in CDMO services. MedPharm is partly owned by Ampersand Capital Partners, Bourne Partners Strategic Capital, and Great Point Partners. The company's unique in vitro testing and research biology models position it as a leader globally, particularly in product development for dermal and transdermal applications.
Sectors
- Pharmaceuticals
- Private Equity
- Healthcare Services
Geography
- United States – MedPharm has significant operations in Durham, NC, and key investors like BPSC are based in the U.S.
- United Kingdom – MedPharm has operations in the United Kingdom, indicating a geographical presence relevant to the article.
- Netherlands – Ampersand Capital Partners has offices in Amsterdam, marking its European presence.
Industry
- Pharmaceuticals – Relevant due to MedPharm's focus on drug development and manufacturing in the pharmaceutical sector.
- Private Equity – Ampersand Capital Partners is a private equity firm involved in the investment in MedPharm.
- Healthcare Services – MedPharm provides contract services across various healthcare delivery methods, such as dermal/transdermal and mucosal.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| MedPharm | Company | Target Company | A global leader in topical and transdermal contract drug development and manufacturing. |
| Bill Humphries | CEO | People | Newly appointed CEO of MedPharm with extensive experience in the pharmaceuticals and life sciences industries. |
| Ampersand Capital Partners | Investor | Company | A middle-market private equity firm investing in MedPharm. |
| Bourne Partners Strategic Capital | Investor | Company | A private equity and growth equity investment firm focused on pharmaceuticals and healthcare. |
| Great Point Partners | Investor | Company | An investor in MedPharm. |
| Pat Walsh | Chairman of the Board | People | Chairman of the Board at MedPharm. |
| Tergus Pharma | Company | Other | A company that merged with MedPharm to enhance its capabilities. |